McKesson (MCK) Stock Forecast & Price Target

Q: What analysts cover McKesson?

McKesson has been rated by research analysts at Barclays , Citigroup , Evercore , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$904.31 +30.52 (+3.49%)

Closing price 03:59 PM Eastern

Extended Trading

$897.64 -6.66 (-0.74%)

As of 05:43 PM Eastern

Compare

McKesson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for MCK.

Consensus Price Target

$973.44
7.64% Upside

According to the 18 analysts' twelve-month price targets for McKesson, the average price target is $973.44. The highest price target for MCK is $1,085.00, while the lowest price target for MCK is $845.00. The average price target represents a forecasted upside of 7.64% from the current price of $904.31.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Analyst Ratings Over Time

Type	Current Forecast 8/25/25 to 8/25/26	1 Month Ago 7/26/25 to 7/26/26	3 Months Ago 5/27/25 to 5/27/26	1 Year Ago 8/25/24 to 8/25/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$973.44	$962.67	$968.87	$725.10
Forecasted Upside	7.64% Upside	14.50% Upside	28.18% Upside	6.74% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Healthcare Companies	Broader Market
Consensus Rating Score	2.78	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	10.00% Upside	822.46% Upside	12.60% Upside
News Sentiment Rating	Very Positive News See Recent MCK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/19/2026	Barclays 3 of 5 stars	Glen Santangelo Not Rated	Boost Target	Overweight	$925.00 ➝ $1,000.00	+14.98%
8/19/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Initiated Coverage	Sector Perform	$845.00	-2.84%
8/11/2026	Wells Fargo & Company 3 of 5 stars	Stephen Baxter 4 of 5 stars	Boost Target	Equal Weight	$812.00 ➝ $933.00	+6.26%
8/7/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$1,015.00	+20.43%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
8/6/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$989.00 ➝ $1,006.00	+15.47%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,050.00 ➝ $1,080.00	+23.97%
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$945.00 ➝ $1,000.00	+21.26%
7/7/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B) ➝ Buy (B-)
Porter flew 3,300 miles to investigate this system (Ad) Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. Watch the full investigation and decide for yourself
5/8/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$875.00	+15.73%
5/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,107.00 ➝ $1,015.00	+37.07%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
4/6/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,040.00 ➝ $1,000.00	+16.29%
3/5/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$970.00	+4.12%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,085.00	+16.60%
2/5/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$880.00 ➝ $885.00	+7.98%
11/25/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/13/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$820.00 ➝ $900.00	+17.07%
4/4/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Sundaram Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:10 PM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 25, 2026. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

The company recently reported strong earnings, with earnings per share (EPS) of approximately $9.93, exceeding expectations, which indicates robust financial performance.
McKesson Co. has shown a year-over-year revenue growth of about 7.7%, suggesting a positive trend in its business operations and market demand.
The current stock price is around $820, reflecting a stable valuation in the healthcare sector, which can be attractive for long-term investors.
McKesson Co. has increased its quarterly dividend to $0.94 per share, demonstrating a commitment to returning value to shareholders, which can be appealing for income-focused investors.
The company has set a positive earnings guidance for FY 2027, projecting EPS between 44.200 and 45.000, indicating confidence in future profitability.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

Despite strong earnings, McKesson Co. has a negative return on equity of over 253%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
The company has a relatively low net margin of 1.12%, indicating that a small portion of revenue is converted into profit, which could limit growth potential.
McKesson Co. has a beta of 0.30, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
The stock has experienced fluctuations, with a fifty-two week range between approximately $673 and $999, indicating potential instability in its market performance.
While the dividend payout ratio is low at 8.78%, it may suggest that the company is retaining most of its earnings for reinvestment rather than returning more to shareholders, which could be a concern for income investors.

MCK Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $973.44, with a high forecast of $1,085.00 and a low forecast of $845.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 7.64% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 downgrade by analysts.

McKesson has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "healthcare" companies. The consensus rating for McKesson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With McKesson Recommendations

MarketBeat monitors more than a dozen sources for McKesson analyst ratings, with the most recent rating issued on 8/19/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target